See Our Other Clinical Research Services:


-Meet Our Team

-About RMC

-Ongoing Research Trials

-More Information

-Closed Research Trials

Ongoing Research Trials Medical Services are available at the following Riverside Medical Clinic locations:


 

Ongoing Research Trials

Allergic Rhinitis

Stallergenes: A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis.

Rheumatoid Arthritis

R-Pharm: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 2 –

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

R-Pharm: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 3 –

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy

R-Pharm:  Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4 –

A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis.

Asthma

Astra Zeneca: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment (ANDHI).

 Asthma

GlaxoSmithKline (Respo):  A randomized, double-blind, parallel group, multicenter, stratified, study evaluating the efficacy and safety of once daily fluticasone furoate/vilanterol inhalation powder compared to once daily fluticasone furoate inhalation powder in the treatment of asthma in participants aged 5 to 17 years old (inclusive) currently uncontrolled on inhaled corticosteroids.

ADHD

Shire: A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years with Attention-Deficit/Hyperactivity Disorder (ADHD).

ADHD

Shire: A Phase 3, Open-label, Multicenter, 12-Month, Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed with Attention-deficit/Hyperactivity Disorder.

SJM Brady MRI Post Approval Study

Abbott:  The study is to evaluate the long term safety of the FDA approved St. Jude Medical Tendril MRI™, Endurity MRI™, or similar model in subjects with a standard bradycardia pacing indication. Additionally, the study will look at how the SJM Brady MRI system works after it has undergone an MRI scan.

Asthma

AstraZeneca: The CHRONICLE Study – A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States.

Asthma

Pearl Therapeutics:  A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma.


Do NOT follow this link or you will be banned from the site!